Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348227 | 0.82 | SMN1; SMN2 (0.39) | SMN1; SMN2LMNAKCNN4GAATP53 | |
| SCHEMBL15823778 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAGAATP53ALDH1A1 | |
| SCHEMBL29348230 | 0.76 | PRKDC (0.32) | SMN1; SMN2 | |
| SCHEMBL5956410 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2CYP2D6CYP2C9KCNN4GAA | |
| SCHEMBL13019293 | 0.72 | SMN1; SMN2 (0.47) | SMN1; SMN2CYP2D6CYP2C9GAAALDH1A1 | |
| SCHEMBL12043652 | 0.72 | RXFP1 (0.44) | SMN1; SMN2LMNACYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL25629019 | 0.71 | GAA (0.41) | SMN1; SMN2LMNAGAATP53MAPT | |
| SCHEMBL29348229 | 0.71 | CYP3A4 (0.36) | SMN1; SMN2LMNACYP2D6CYP2C9GAA | |
| SCHEMBL12339193 | 0.70 | USP1 (0.38) | CYP2D6CYP2C9KCNN4TSHR | |
| SCHEMBL23563041 | 0.70 | SMN1; SMN2 (0.44) | SMN1; SMN2CYP2D6CYP2C9GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |